API

Deferasirox, marketed under the brand Refarmed Chemicals, is a cornerstone in the treatment of chronic iron overload due to blood transfusions in conditions such as thalassemia and sickle cell disease. This condition, if not properly managed, can have severe consequences for organ function. Deferasirox is available in oral tablet form, with strengths of 250 mg, 500 mg, and 1000 mg, allowing for flexibility and precision in dosing to meet individual patient needs. Crafted as an iron chelator, Deferasirox plays a crucial role in binding excess iron within the body and facilitating its excretion through urine. This targeted mechanism asserts its importance in maintaining a healthy balance of iron and preventing the potential toxicity associated with overload. Patients are advised to take Deferasirox with or without food, adhering to a dosing schedule that is tailored to their specific iron levels and bodily response, underscoring the need for a personalized approach to treatment. Regarding its physical properties, Deferasirox appears as a white to pale yellowish crystalline powder, primarily soluble in DMF (Dimethylformamide) and slightly soluble in methanol. These characteristics are essential for ensuring its effectiveness and stability as a pharmaceutical agent. It is imperative that patients undergo regular blood tests and health monitoring for optimum results and to prevent adverse effects such as gastrointestinal distress, skin reactions, and potential liver or renal impairment. Additionally, care must be taken in cases of known hypersensitivity to Deferasirox or pre-existing severe renal or liver conditions. Our documentation and certifications like Good Manufacturing Practice (GMP) and the Drug Master File (DMF) guarantee the highest levels of quality and compliance with industry standards. It is our priority to ensure that this crucial pharmaceutical material is of the utmost purity and efficacy, as reflected in our stringent quality control parameters including the presence of residual solvents and related substances, all documented for your assurance. Please note that while Deferasirox is a vital medication for many patients, it requires diligent medical supervision. Always consult healthcare professionals for specific medical advice and treatment instructions tailored to individual health profiles.

Products still subject to third-party patent protection might be available solely for R&D purposes.

**Product Overview: Febuxostat – A Robust Solution for Gout Management** Refarmed Chemicals presents Febuxostat, a meticulously prepared medication aimed at alleviating the pain and discomfort associated with gout. Made from a refined white powder, Febuxostat stands out in the pharmaceutical industry as a Xanthine Oxidase Inhibitor, crucial for managing hyperuricemia and recurrent gout attacks. Structured to meet corporate expectations, Febuxostat is a testament to Refarmed Chemicals' 30-year expertise in delivering quality generic and branded medications. Manufactured in compliance with strict guidelines, including the Drug Master File (DMF) and certifications such as WC and GMP, this product is a model of reliability and efficacy. Febuxostat's fundamental use is to decrease blood uric acid levels, offering those afflicted with gout a pathway to recovery by preventing acute flare-ups, and mitigating inflammation and pain in the joints. As a white, soluble powder, Febuxostat is highly soluble in DMSO and slightly soluble in methanol and water, simplifying its integration into diverse medical formulations. Clinical trials have informed a standard starting dosage of 40 mg, adjustable up to 80 mg based on individual patient requirements and the severity of symptoms. In its commitment to patient welfare, Refarmed Chemicals underlines potential side effects ranging from nausea and headaches to rashes, ensuring informed usage of Febuxostat. In alignment with our promise of transparency and safety, we advise consulting healthcare professionals for precise diagnotics and treatment plans. Furthermore, users should be attentive to contraindications, noting that Febuxostat is unsuitable for patients with severe liver or kidney disease, or for women who are pregnant or breastfeeding. Refarmed Chemicals' Febuxostat exceeds industry standards with its impressive assay value of 98.0% - 102.0% purity and a precise control of impurities, ensuring that the product meets stringent quality criteria. The company's analytical rigor is reflected in the detailed specification of residual solvents such as Acetone, Ethanol, and Isopropanol. In the journey to deliver improved health outcomes, Refarmed Chemicals' Febuxostat is more than just a medication; it symbolizes our dedication to quality, safety, and corporate responsibility in the global pharmaceutical landscape. [*Note: Product image depicts a detailed specification chart for Febuxostat, reiterating its quality and compositions.*]

Products still subject to third-party patent protection might be available solely for R&D purposes.

Refarmed Chemicals is proud to present its esteemed pharmaceutical compound, Butamirate Citrate, an integral antitussive agent designed to alleviate discomfort in patients suffering from dry, unproductive coughs. Our Butamirate Citrate is an optimal choice for those grappling with upper respiratory tract infections, bronchitis, pneumonia, and even asthma, providing relief from persistent coughing that often accompanies these conditions. Crafted with meticulous attention to quality, our Butamirate Citrate appears as a white to yellowish powder with a slightly waxy texture, assuring ease of incorporation into various dosage forms. Its chemical identity is confirmed through rigorous testing, including the citrate and IR tests, maintaining a high level of purity and performance. The compound exhibits excellent solubility, being freely soluble in water and ethanol (96%), which ensures flexibility in formulation. Adhering to the gold standard of production, Butamirate Citrate holds GMP certification and is characterized by a precise pH range of 3.5 to 4.0. Our commitment to safety and efficacy is evidenced by the thorough analysis that guarantees an assay value between 98.0% - 102.0%, with minimal impurities. Heavy metals content is strictly controlled to ensure patient safety, and residual solvents such as Isopropanol, MTBE, Isopropyl ether, and Toluene are meticulously regulated. Our Butamirate Citrate operates by targeting the cough center in the medulla oblongata to effectively suppress cough reflexes, without reliance on opioids. This action provides a duration of relief for 4-8 hours, allowing for a more comfortable recovery process for the patient. It is suitable for adults and children over the age of 6, with dosage adjustments available to accommodate individual patient responses and tolerability. In conclusion, Refarmed Chemicals' Butamirate Citrate stands as a testament to our dedication to delivering pharmaceutical ingredients of the highest caliber. Our product not only meets the robust demands of the pharmaceutical industry but also provides a critical component for the formulation of efficacious cough suppressants that cater to a wide range of patients.

Products still subject to third-party patent protection might be available solely for R&D purposes.

Benserazide Hydrochloride, offered under REFARMED CHEMICALS—a subsidiary of the DKSH Group—is an essential pharmaceutical ingredient tailored for the robust demands of the medical industry. Specifically formulated for the management of Parkinson’s disease, Benserazide Hydrochloride serves as a monoamine oxidase B (MAO-B) inhibitor. When synergistically combined with levodopa, it not only amplifies the efficacy of the treatment but also mitigates associated side effects such as nausea, enhancing the quality of life for patients suffering from this neurodegenerative condition. Our Benserazide Hydrochloride emerges as a white to off-white crystalline powder, a testament to its purity and quality. The compound exhibits admirable water solubility, ensuring ease of formulation and bioavailability. Its molecular identity, C10H14N2O3·HCl, with a molecular weight of 234.7 g/mol, aligns with rigorous pharmaceutical prerequisites. Our product delivers through a strict adherence to quality with an assay value ranging from 98.5% to 101.0%, guaranteeing a high-caliber substance with minimal impurity content. REFARMED CHEMICALS prioritizes safety and compliance, validating Benserazide Hydrochloride's authenticity with the IR and Chlorides test among others, and acknowledges the product’s conscientious solubility in water and minimal solubility in anhydrous ethanol. We maintain stringent control on residual solvents, ensuring ethanol levels remain below 5000 ppm and methanol below 3000 ppm. Administered orally, this pharmaceutical agent's dosage is contingent upon individual patient needs and medical recommendations, subject to professional healthcare guidance. Despite its profound benefits, it should be noted that Benserazide Hydrochloride is contraindicated for patients with severe hepatic or renal impairments and requires cautious use in patients with a history of cardiovascular diseases, orthostatic hypotension, or psychiatric conditions. Interaction with opioids and antidepressants necessitates careful management. Upholding the highest standards, our product is compliant with Good Manufacturing Practice (GMP) and holds the Certificate of Suitability (CEP)—a rigorous certification ensuring consistency in high-quality production for our corporate customers. With REFARMED CHEMICALS, you are guaranteed a product that not only addresses the therapeutic needs but also embodies the precision and reliability sought after in the pharmaceutical industry.

Products still subject to third-party patent protection might be available solely for R&D purposes.